Nicholas Appelbaum

Co-founder & CEO at Dosium | Honorary Research Fellow, Institute of Global Health Innovation, Department of Surgery and Cancer at Imperial College London | MBChB MRCS FBCS PhD

Nicholas Appelbaum is the Co-Founder and CEO of Dosium, a company that specializes in clinical decision support technology aimed at improving the speed, consistency, and safety of prescribing medications.1 2

Professional Background

Appelbaum's work focuses on addressing the critical issue of medication errors in healthcare. He has highlighted that deaths due to medication errors are comparable to the annual number of deaths from road traffic accidents in the UK.1 2

Dosium's Technology

Under Appelbaum's leadership, Dosium has developed a unique solution called Touchdose. This technology:

Automatically calculates the correct dosage of any drug for individual patients
Uses an exclusive integration with the British National Formulary (BNF) and BNF for Children (BNFC)
Incorporates local guidelines in its calculations1 2

Academic Affiliation

In addition to his role at Dosium, Appelbaum holds the position of Honorary Research Fellow at Imperial College London's Institute of Global Health Innovation.4

Recent Developments

In August 2024, Appelbaum's company received a landmark investment from the Royal Pharmaceutical Society (RPS), through its knowledge business Pharmaceutical Press. This investment is intended to support the development of electronic prescribing solutions driven by BNF and BNFC.1 2

Social Media Presence

Appelbaum maintains a professional presence on social media platforms:

LinkedIn: His profile can be found under the username nicholas-appelbaum-345482363
Twitter: He uses the handle @nicapples4

Through his work at Dosium, Appelbaum aims to revolutionize clinical decision support systems in the UK and increase patient safety by reducing avoidable harm caused by prescribing errors.1 2